Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2

U Bertsch¹, C Röder¹, H Kalthoff¹ and A Trauzold*¹

Localized in the plasma membrane, death domain-containing TNF-related apoptosis-inducing ligand (TRAIL) receptors, TRAIL-R1 and TRAIL-R2, induce apoptosis and non-apoptotic signaling when crosslinked by the ligand TRAIL or by agonistic receptor-specific antibodies. Recently, an increasing body of evidence has accumulated that TRAIL receptors are additionally found in noncanonical intracellular locations in a wide range of cell types, preferentially cancer cells. Thus, besides their canonical locations in the plasma membrane and in intracellular membranes of the secretory pathway as well as endosomes and lysosomes, TRAIL receptors may also exist in autophagosomes, in nonmembraneous cytosolic compartment as well as in the nucleus. Such intracellular locations have been mainly regarded as hide-outs for these receptors representing a strategy for cancer cells to resist TRAIL-mediated apoptosis. Recently, a novel function of intracellular TRAIL-R2 has been revealed. When present in the nuclei of tumor cells, TRAIL-R2 inhibits the processing of the primary let-7 miRNA (pri-let-7) via interaction with accessory proteins of the Microprocessor complex. The nuclear TRAIL-R2-driven decrease in mature let-7 enhances the malignancy of cancer cells. This finding represents a new example of nuclear activity of typically plasma membrane-located cytokine and growth factor receptors. Furthermore, this extends the list of nucleic acid targets of the cell surface receptors by pri-miRNA in addition to DNA and mRNA. Here we review the diverse functions of TRAIL-R2 depending on its intracellular localization and we particularly discuss the nuclear TRAIL-R2 (nTRAIL-R2) function in the context of known nuclear activities of other normally plasma membrane-localized receptors.

Cell Death and Disease (2014) 5, e1390; doi:10.1038/cddis.2014.351; published online 28 August 2014

Facts

- Plasma membrane-located TRAIL-R1/R2 induce both cell death and non-apoptotic signaling pathways.
- Tumor cells show elevated intracellular levels of TRAIL-R1/R2.
- Nuclear TRAIL-R2 interacts with the Microprocessor complex, inhibits let-7 maturation and enhances tumor cell proliferation.

Open Questions

- What is the mechanism of nuclear import/export of TRAIL-R2 and how is this regulated?
- Which miRNAs, beside let-7, are regulated by nTRAIL-R2?
- What are additional specific functions of nTRAIL-R2? Is there any impact of other TRAIL-Rs (TRAIL-R1, -R3 and -R4) on nuclear localization and function of TRAIL-R2?
- Do TRAIL-R1, TRAIL-R3 and TRAIL-R4 possess independent specific nuclear activities?
- Is there a specific function of cytoplasmic TRAIL death receptors?

The death ligand TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine superfamily, interacts with five different receptors, plasma membrane-expressed TRAIL-R1-4 and a soluble receptor, osteoprotegerin (OPG), all members of the TNF receptor superfamily.¹⁻³ Two TRAIL receptors, TRAIL-R1/DR4 and TRAIL-R2/DR5/TRICK/Killer, contain a cytoplasmic death domain (DD) and are hence able to induce apoptosis.¹⁻³ Therefore, they are also referred to as the TRAIL death receptors.

TRAIL has governed particular interest because of its apparent tumor cell-specific apoptosis-inducing capacity.⁹,¹⁰ Consequently, TRAIL and agonistic TRAIL death receptor-specific antibodies are regarded as promising therapeutic

¹Division of Molecular Oncology, Institute for Experimental Cancer Research, University of Kiel, Kiel D-24105, Germany
*Corresponding author: A Trauzold, Division of Molecular Oncology, Institute for Experimental Cancer Research, University of Kiel, Arnold-Heller Strasse 3 (Haus 17), Kiel D-24105, Germany. Tel: +49 431 597 1962; Fax: +49 431 597 1939; E-mail: atrauzold@email.uni-kiel.de

Abbreviations: APAF-1, apoptotic protease activating factor-1; DED, death effector domain; DISC, death-inducing signaling complex; ERK1, extracellular regulated kinase-1; FADD, Fas-associated protein with death domain; cFLIP, cellular flice-like inhibitory protein; HtrA2/Omi, high temperature requirement protein A2/Omi; JNK, c-Jun N-terminal kinase; LMP, lysosomal membrane permeabilization; miRNA, microRNA; MLKL, mixed lineage kinase domain-like; MOMP, mitochondrial outer membrane permeabilization; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; OPG, osteoprotegerin; PACS-2, phosphofurin acidic cluster sorting protein-2; PKB, protein kinase B; PKC, protein kinase C; RIP-1, receptor-interacting protein-1; Smac/Diablo, second mitochondria-derived activator of caspase/direct; IAP, binding protein with low pI; TRAIL, TNF-related apoptosis-inducing ligand

Received 02.5.14; revised 09.7.14; accepted 10.7.14; Edited by H-U Simon
agents for treatment of various malignancies and are currently under clinical investigation. However, many tumor cells are resistant to TRAIL-mediated apoptosis and, furthermore, TRAIL death receptors may induce pro-inflammatory, invasion- and metastasis-promoting non-apoptotic signaling pathways under certain conditions. These observations point to the necessity to improve TRAIL-R1/R2-targeting therapies by combination with molecules sensitizing to cell death and at the same time inhibiting potentially harmful non-apoptotic signaling.

Overexpression of TRAIL-R1 and/or TRAIL-R2 has been demonstrated for many tumor entities (Table 1). Importantly, these studies detected mainly an intracellular localization of the receptors, suggesting that intracellular TRAIL-R1 and TRAIL-R2 may provide a growth advantage or other benefit for tumor cells. Indeed, correlation of the expression status with clinical parameters disclosed prevalent prognostic significance of high death receptor expression, identifying predominantly TRAIL-R2 and occasionally also TRAIL-R1 as negative prognostic markers (Table 1). For example, high TRAIL-R2 expression correlated with higher tumor grade, positive nodal status and shortened survival of breast cancer patients. Strong TRAIL-R2 expression also negatively correlated with disease-free survival of patients suffering from metastatic HNSCC. For stage I and II NSCLC, high TRAIL-R2 expression correlated with poorly differentiated tumors and significantly reduced patient survival. Similarly, poorly differentiated areas of stage III NSCLC showed high expression of TRAIL-R1 and TRAIL-R2, but only TRAIL-R2 positivity was associated with an increased risk of death. Moreover, pancreatic cancer cells with stem cell characteristics also express TRAIL-R2 at increased levels. Correspondingly, high intracellular expression of TRAIL-R2 has been demonstrated for stem cells at the base of the intestinal crypts in the small intestine.

Reports of positive correlation between receptor expression and better prognosis are occasionally also found. Thus, TRAIL-R1 was identified as an independent prognostic marker for a more favorable course of colorectal carcinoma. In bladder cancer, higher levels of either TRAIL-R1 or TRAIL-R2 correlated with longer recurrence-free survival. In glioblastoma multiforme, high expression of both TRAIL-R1 and TRAIL-R2, of note mainly expressed at the cell surface, was found to be associated with longer overall survival of the respective patients.

So far, mainly the overall tissue expression level of TRAIL receptors and occasionally also their presence at the cell surface were taken into account when estimating their values as a prognostic marker for cancer. However, recent discoveries on TRAIL-R2 functions revealed that even though an

**Table 1** Intracellular detection of TRAIL death receptors in human tissues

| Tissue                   | Cell compartment | TRAIL-R | Clinical relevance                                                                                                | Reference |
|--------------------------|-----------------|---------|---------------------------------------------------------------------------------------------------------------|-----------|
| Colorectal carcinoma     | Cytoplasm       | 1, 2    | Less progressive disease in high expressers of TRAIL-R1 during 5-FU therapy                                    | 18, 19    |
| Colorectal carcinoma     | Cytoplasm       | 1, 2    | TRAIL-R1 is an independent prognostic marker for better prognosis                                             | 58        |
| Colon cancer             | Cytoplasm       | 1, 2    | ND                                                                                                            | 64        |
| Breast cancer            | Cytoplasm/nucleus| 1, 2    | TRAIL-R1 expression positively correlates with tumor grade                                                   | 60        |
| Breast cancer            | Cytoplasm       | 1, 2    | High TRAIL-R2 expression correlates with poor prognosis                                                        | 20, 21    |
| Renal carcinoma          | Cytoplasm       | 1, 2    | High expression of nuclear and cytoplasmic TRAIL-R2 correlates with improved patient survival                  | 61        |
| Non-small-cell lung cancer| Cytoplasm/nucleus| 1, 2    | High TRAIL-R2 expression correlates with poorly prognosis                                                      | 27        |
| Non-small-cell lung cancer| Cytoplasm       | 1, 2    | High TRAIL-R2 expression correlates with poor prognosis                                                        | 28        |
| Melanoma                 | Cytoplasm       | 1, 2    | High TRAIL-R2 expression correlates with better prognosis                                                      | 68        |
| Pancreatic ductal adenocarcinoma | Cytoplasm   | 1, 2    | Plasma membrane expression of TRAIL-R2 correlates with better prognosis in patients without nodal metastases at the time of surgery | 17        |
| Pancreatic ductal adenocarcinoma | Cytoplasm  | 1, 2    | High nuclear TRAIL-R2 expression correlates with poor prognosis of patients with early stages                   | 16        |
| Glioblastoma multiforme  | Cytoplasm       | 1, 2    | High TRAIL-R1 expression correlates with better prognosis                                                      | 22        |
| Head and neck squamous cell carcinoma | Cytoplasm | 2       | High TRAIL-R2 expression in primary tumors without metastasis correlates with better prognosis, but high TRAIL-R2 expression in tumors with metastasis correlates with worse prognosis | 23        |
| Oral squamous cell carcinoma | Cytoplasm     | 1, 2    | High TRAIL-R2 expression correlates positively with tumor size                                                 | 26        |
| Cervical cancer          | Cytoplasm       | 1, 2    | High expression but no prognostic relevance                                                                  | 24        |
| Bladder cancer           | Cytoplasm       | 1, 2    | High TRAIL-R1 and -R2 expression correlates with better prognosis                                            | 29        |
| Normal and psoriatic skin lesions | Cytoplasm | 1, 2    | ND                                                                                                            | 70        |
| CD68 + cells in psoriatic skin lesions | Cytoplasm | 2       | ND                                                                                                            | 70        |
| CD4 + and CD8 + cells in psoriatic skin lesions | Cytoplasm | 1       | ND                                                                                                            | 70        |

Abbreviation: ND, not determined

*(Only intracellular compartments are listed. In many cases, TRAIL death receptors were also observed at the plasma membrane. ‘Cytoplasm’ may comprise all intracellular localizations except the nucleus, as immunohistochemical analyses normally do not discriminate between membranous cytoplasmic compartments and cytosol.*
enormous body of information on death receptors has been gathered, our knowledge of the cellular functions of these receptors is still incomplete. The authors report that nuclear TRAIL-R2 (nTRAIL-R2) is engaged in microRNA (miRNA) maturation, thus performing functions entirely different from its classical role as a plasma membrane-located signal transducer. With this finding, the frequently observed high intracellular expression of TRAIL-Rs in tumors gains importance and demands careful re-evaluation.

Here we review the known functions of human TRAIL death receptors with respect to their subcellular compartmentalization. The novel nuclear functions of TRAIL-R2 will be discussed in comparison to nuclear functions of other conventionally plasma membrane-located cytokine and growth factor receptors.

### TRAIL Receptors and Their Classical Functions at the Plasma Membrane

The best understood function of TRAIL-R1 and TRAIL-R2 is the induction of apoptosis (reviewed in Gonzalvez and Ashkenazi32 and see Figure 1). Upon TRAIL ligation, TRAIL death receptors cluster into higher multimeric complexes and gain the capability of assembling a DISC (death-inducing signaling complex) at their intracellular DD. Through this domain, TRAIL-R1 and TRAIL-R2 recruit the adaptor protein FADD (Fas-associated protein with death domain) that in turn, via death effector domain (DED), recruits the inactive pro-forms of the initiator caspases pro-caspase-8 and -10. Proximity-induced self-cleavage of pro-caspases within the DISC leads to their activation and subsequent dissociation from the membrane-localized receptor complexes.

Besides death receptors, TRAIL can also bind to two additional plasma membrane-bound receptors, TRAIL-R3 and TRAIL-R4. TRAIL-R3 is a glycosylphosphatidylinositol-anchored receptor lacking transmembrane and cytoplasmic domains and is therefore not capable of inducing intracellular signaling. TRAIL-R4 is more homologous to the TRAIL death receptors, but because of a truncated DD, it is unable to induce apoptosis.4,6

Efficiency of the initiator caspase activation may be influenced at the DISC level, for example, by variation of its composition. It has been shown that the complex formation between death receptors TRAIL-R1 and TRAIL-R2 and the apoptosis-incompetent receptors, TRAIL-R3 or TRAIL-R4, leads to impaired DISC function.33,34 In addition, recruitment of the proteolytically inactive caspase homolog cFLIP (cellular FLICE-like inhibitory protein) represents an apoptosis-inhibiting mechanism.35,36

In some cells, activated initiator caspases may directly activate the effector caspases -3, -6 and -7, which in turn cleave a broad range of protein substrates and execute cell death. Such cells have been classified as the so-called type I cells with respect to apoptosis induction.37 In contrast, type II cells use the loop way via engagement of the intrinsic apoptosis pathway to amplify the death signal generated at the DISC. In these cells, caspase-8-mediated cleavage of the BH3-only protein Bid generates its truncated form (tBid) that, by association with Bax and Bak, leads to the mitochondrial outer membrane permeabilization (MOMP) and to the release of pro-apoptotic mitochondrial proteins like cytochrome C, Smac/Diablo (second mitochondria-derived activator of caspase/direct IAP binding protein with low pI) and HtrA2/Omi (high temperature requirement protein A2/Omi) into the cytosol. Cytosolic cytochrome C together with ATP and Apaf-1 (apoptotic protease activating factor-1) form a second caspase-inducing platform, the Apoptosome, that mediates the activation of caspase-9. Caspase-9, in turn, acts as an initiator caspase activating the effector caspases.

![Figure 1](image-url) Functions of plasma membrane-localized TRAIL death receptors. Following binding of their ligand, TRAIL death receptors TRAIL-R1 and TRAIL-R2 are able to induce cell death (apoptosis or necroptosis). Alternatively, these receptors may also enhance cell proliferation, inflammation, migration and invasion via activation of multiple ‘non-death-inducing’ signal transduction pathways. LMP, lysosomal membrane permeabilization; MOMP, mitochondrial outer membrane permeabilization.
An alternative TRAIL-induced apoptosis pathway has been described in hepatocytes (Figure 1). In these cells, TRAIL-R2 is internalized upon TRAIL stimulation by endocytosis, targeted via vesicular transport to lysosomes that become permeabilized and release cathepsin B, subsequently promoting cell demise. Lysosomal membrane permeabilization (LMP) as a precondition for the execution of apoptosis in these cells requires the PACS-2 (phosphofurin acidic cluster sorting protein 2)-mediated recruitment of Bim and Bax to lysosomal membranes.

Under conditions when caspases are inhibited, plasma membrane-expressed TRAIL death receptors may also induce an alternative death pathway known as necroptosis. For this pathway, a pivotal role of the kinases RIP-1 (receptor-interacting protein-1), RIP-3 as well as pseudo-kinase MLKL (mixed lineage kinase domain-like) has been shown, but the exact molecular mechanisms of TRAIL-induced necroptosis are still not fully understood.

Over the past years, it has become increasingly evident that TRAIL-R1 and TRAIL-R2, besides death signaling pathways, can also activate multiple non-cell death signal transduction pathways like NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells), PKC (protein kinase C), PI3K (phosphatidylinositide 3-kinases), AKT/PKB, Src (Rous sarcoma virus oncogene cellular homolog) and TAK1 (transforming growth factor-β activated kinase 1), as well as different members of the MAP-kinase family like ERK1/ERK2 (extracellular regulated kinase), JNK (c-Jun N-terminal kinase) and p38 (Figure 1).

Regarding the molecular determinants for TRAIL-mediated activation of cell death or non-apoptotic pathways, the engagement of different protein complexes has been proposed. In this respect, non-apoptotic pathways have been suggested to be activated within a secondary signaling complexes formed downstream of the DISC. Besides FADD and pro-capase-8, the secondary signaling complex also include specific adaptor proteins like RIP1, TRAF2 and Nemo.

Different localizations of aggregated TRAIL receptors within specific plasma membrane domains have also been proposed to determine the formation and activity of ligand-induced TRAIL-R1/R2 signaling complexes. Hence, aggregated TRAIL receptors localized in lipid rafts were shown to be involved in the apoptotic signaling, whereas those localized outside lipid rafts form complexes capable of non-apoptotic signaling.

Alternative to the MAPKs activation via secondary protein complexes, their stimulation via effector caspases was described in prostate cancer cells. Here, two different proteolytic fragments of Mst1 (mammalian sterile 20-like kinase 1) generated upon cleavage by caspases-3 or -7 selectively activate ERK or JNK and p38, respectively.

This multiplicity and heterogeneity of TRAIL-induced pathways, as briefly outlined, is responsible for the observed broad cellular effects of this cytokine ranging from the induction of cell death, establishment of a death-resistant phenotype and expression of pro-inflammatory molecules promoting cell proliferation, migration and invasion (Figure 1). Particularly in apoptosis-resistant tumor cells, TRAIL-induced pro-inflammatory pathways may result in enhanced invasion and metastasis in vivo. A comprehensive overview of TRAIL-induced non-apoptotic signaling pathways and their functional relevance in different cellular systems is provided in the recent review by Azijli et al.

**Cytoplasmic Locations and Functions of TRAIL Death Receptors**

In addition to their plasma membrane expression, TRAIL-R1 and TRAIL-R2 are also often found in the cytoplasm of several cell types (Tables 1 and 2). However, in most cases the cytoplasmic localization of TRAIL death receptors was not resolved in detail. Thus, it still remains unclear whether the intracellular staining in cancer cells observed by immunohistochemistry reflects localization of TRAIL receptors in the membranes of organelles within the secretory and/or endocytotic pathway or whether a non-membranous cytosolic localization of the receptors was also detected in these cases. The presence of TRAIL-R1 and TRAIL-R2 in soluble cytosolic fractions of diverse tumor cells was demonstrated recently. As the subcellular fractionation was performed without the any detergent, it can be concluded that these receptors are not anchored in intracellular membranes, but are present in the non-membranous cytosolic compartment. The function of these soluble TRAIL death receptors remains to be shown.

In colon carcinoma, the cytoplasmic staining of TRAIL death receptors was interpreted as the presence of these receptors in the trans-Golgi network, a finding previously described for melanoma cells. The study on apoptosis-resistant breast cancer cells demonstrated the presence of TRAIL receptors in autophagosomes rather than the plasma membrane. Treatment of these cells with different inhibitors of autophagy led to a re-appearance of both TRAIL death receptors on the cell surface and sensitized these cells toward TRAIL-mediated death. A correlation of apoptosis resistance with intracellular presence of death receptors in breast cancer cells was also proposed in another study. Finally, as internalization of TRAIL death receptors in response to TRAIL treatment has been demonstrated in cell lines, the cytoplasmic localization of TRAIL receptors in tumor tissue could be caused by an autocrine or paracrine activation of their internalization by stroma and/or tumor cell-derived TRAIL. So far, however, this remains speculation and needs further investigation. Summing up, despite the variety of intracellular TRAIL death receptor locations, the frequently observed loss of TRAIL death receptors at the cell surface in tumors seems to be a general principle for the acquisition of TRAIL resistance in cancer cells. In addition, high cytoplasmic levels of these receptors as well as their presence in soluble form suggest specific pro-tumoral functions in this location.

**TRAIL Death Receptors in the Nucleus**

Few relatively recent studies show the localization of TRAIL receptors in the nucleus (Tables 1 and 2). An early report on the melanoma cell line, Mel-FH, demonstrated TRAIL-R1 as predominantly expressed in the nucleus, where it colocalized with TRAIL-R3 and TRAIL-R4. Nuclear presence of TRAIL-R1 and TRAIL-R2 has also been shown for normal and psoriatic skin, with nTRAIL-R2 being more
strongly expressed in psoriatic lesions and in the dermis of psoriatic skin compared with healthy skin. In the same study, CD4+ and CD8+ cells of the inflammatory infiltrate showed exclusive nuclear staining for TRAIL-R1. Nuclear presence of TRAIL-R2 was also described for nonmalignant, normal lung bronchial epithelial cells in basal nuclei. However, staining of these cell nuclei was in general weak and restricted to a small number of cells.

Only very few studies have addressed the functional relevance of nTRAIL-R2. Again, as for the presence of TRAIL-R1/R2 in the cytoplasm, the nuclear sequestration has been proposed as an apoptosis-resistance mechanism. Trophoblast cells of the human placenta were found resistant to TRAIL-mediated apoptosis and expressed high levels of TRAIL-R2 that was mainly localized in the nucleus. TRAIL-R1/R2 in the cytoplasm, the nuclear sequestration has been proposed as an apoptosis-resistance mechanism. In one report, the pattern of intracellular distribution of TRAIL-R during the development of the mouse CNS was studied. The authors demonstrated that the expression of TRAIL-R was not only restricted to proliferating zones but, importantly, was mainly located in the cell nuclei, suggesting a specific, proliferation-associated function of nTRAIL-R. Another study investigating human nuclear TRAIL receptors finally uncovered specific functions of nTRAIL-R2 connecting this receptor to the process of miRNA maturation (Figure 2). Briefly, in several different tumor cells, nTRAIL-R2 interacts with the core Microprocessor complex Drosha/DGCR8 and with several of its accessory proteins, p68, NF45 and hnRNPA1. Through this interaction, nTRAIL-R2 inhibits maturation of the miRNA let-7 and consequently increases the levels of let-7 targets Lin28B and HMGA2. HMGA2 and Lin28B proteins are highly expressed in embryonic tissues, downregulated in differentiated tissues and, because of low expression of let-7, re-expressed in tumors, where their levels positively correlate with tumor progression. In this scenario, inhibition of let-7 maturation by nTRAIL-R2 enhances the malignancy of tumor cells. In line with this notion, it was observed that TRAIL-R2 was expressed at higher levels in cell nuclei of PDAC tissue than in nuclei of peritumoral normal duct cells. In these patients, however, high nuclear and cytoplasmic expression of TRAIL-R2 correlated with improved survival. However, it is well known that chemotherapeutic agents upregulate TRAIL-R2 in cells with wild-type p53. Unfortunately, the p53 status was not analyzed in this study and it may be possible that the observed positive correlation simply reflects the better prognosis of patients with wild-type p53. In agreement with this interpretation, other studies on untreated lung cancer patients, as well as patients suffering from other cancers, have instead found negative

| Cell line / cells: origin | Cell compartment | TRAIL-R | Proposed function | Reference |
|--------------------------|-----------------|---------|-------------------|-----------|
| HCT116; colorectal carcinoma | Cytoplasm, Nucleus | 1, 2 | ND, Inhibition of let-7 maturation | 16, 59 |
| MDA-MB-231; breast cancer | Cytoplasm, Nucleus | 1, 2 | ND, Inhibition of let-7 maturation | 16, 66 |
| Panc, Colo357, A818-6; pancreatic cancer | Cytoplasm, Nucleus | 1, 2 | ND, Inhibition of let-7 maturation | 16, 69 |
| AU565, BT474, HCC1428, MDA-MB-453, MDA-MB-361; breast cancer | Cytoplasm, Nucleus, Autophagosomes, Lysosomes | 1, 2 | Resistance to TRAIL-mediated apoptosis, Correlation with TRAIL-mediated apoptosis, Resistance to TRAIL-mediated apoptosis, Resistance to TRAIL-mediated apoptosis | 65, 66, 67, 68 |
| Placental primary cytotrophoblast cells | Nucleus, Lysosomes | 2 | Inhibition of let-7 maturation, TRAIL-R2-dependent lysosomal permeabilization promotes apoptosis | 59, 66, 67, 68 |
| Huh-7; hepatocellular carcinoma | Nucleus, Cytoplasm | 1, 2 | Resistance to TRAIL-mediated apoptosis, Resistance to TRAIL-mediated apoptosis | 69, 69 |
| HepG2; hepatocellular carcinoma | Nucleus | 2 | Resistance to TRAIL-mediated apoptosis | 69 |
| HeLa; cervix carcinoma | Nucleus | 2 | Resistance to TRAIL-mediated apoptosis | 69 |
| Mel-FH; melanoma | Nucleus | 1 | ND | 65 |

Abbreviation: ND, not determined

*Only intracellular compartments are listed. In many cases, TRAIL death receptors were also observed at the plasma membrane. 'Cytoplasm' may comprise all intracellular localizations except the nucleus, as immunodetection normally does not discriminate between membranous cytoplasmic compartments and cytosol.*
correlations between high overall expression of TRAIL-R2 and the survival time of the patients.

The nuclear presence of TRAIL death receptors represents a new example of plasma membrane receptors that can localize to the nucleus, where they elicit functions distinct from their canonical signal transduction pathways that originate at the plasma membrane. Most prominently, the receptor tyrosine kinases (RTKs), and among them the members of the epidermal growth factor receptor (EGFR) family, have been found to shuttle to the nucleus in response to ligand binding (reviewed by Carpenter and Liao74 and Wang et al.75). Here, via interaction with classical transcription factors or with RNA helicase A (RHA), nuclear EGFRs activate the expression of several target genes.76–81 In addition, via interaction with RNA-polymerase I, EGFR2 increases rRNA expression and cellular translation.82 EGFRs may also phosphorylate nuclear proteins such as PCNA,83 and DNA-dependent protein kinase (DNA-PK),84–86 thus influencing a variety of other nuclear processes like DNA replication and DNA damage repair.

Other RTKs found in the nucleus are fibroblast growth factor receptors (FGF-R1, -R2 and -R3; reviewed by Bryant and Stow87) vascular endothelial growth factor receptors (VEGF-R1, see Cai et al.88 and VEGF-R2, see Shay-Salit et al.89) insulin receptor,90 cMet,91 TrkA,92 growth hormone receptor 93 and receptor tyrosine kinase-like orphan receptor 1 (Ror1).94 Particularly well understood are functions of nuclear FGF-R1 that, via its interaction with 90-kDa ribosomal S6 kinase (RSK1), activates the transcription factor CREB, thus regulating the transcription of genes involved in proliferation and differentiation.95 As RSK1 phosphorylates several transcription factors as well as histone H3, the ability to activate RSK1 enables nuclear FGF-R1 to regulate a plethora of biological processes.

Besides RTKs, other types of cell surface transmembrane receptors have also been described as being localized in the nucleus. Type I transforming growth factor β receptor (TβR1) can localize to the nucleus following TGF-β treatment,96 where it can interact with hnRNPA1, thus stimulating the alternative splicing of pre-mRNA for EGFR1.97 It is noteworthy that hnRNPA1, besides its known regulatory role in splicing, was also described as an accessory protein of the Microprocessor complex interacting with nTRAIL-R2 in this context.16 However, in contrast to the findings for TRAIL-R2, no association of TβR1 with miRNA maturation has been described till now.

CD40 and the B cell-activating factor receptor (BAFF-R), both members of the TNF receptor superfamily, also localize to the nucleus in normal and malignant B cells, in addition to their plasma membrane expression. In the nucleus, these receptors interact with c-Rel and enhance transcription of several NF-κB target genes.98,99 Nuclear BAFF-R, in addition, interacts with IKK-β and histone H3, leading to increased IKK-β-mediated phosphorylation of histone H3.99

The surprising role of nTRAIL-R2 in regulating let-7-maturation strongly demands future research on the mechanisms of intracellular trafficking of this receptor. Regarding the mechanism by which full-length plasma membrane receptors passage to the nucleus, the intracellular trafficking of RTKs might serve as a model. Following ligand binding at the cell surface, EGFRs are internalized via endocytosis, moved by retrograde transport in endosomal vesicles into the ER and subsequently translocated through the ER membrane into the cytosol by action of the Sec61 translocon.100 Free cytosolic full-length receptors can then be bound at their tripartite nuclear localization motif (NLS) by β-importin and finally imported into the nucleus through the nuclear pore.
complex.\textsuperscript{101} An alternative model for the entry of full-length EGFR family members into the nucleus involving a passage of these receptors into the nucleoplasm through a Sec61 translocon in the inner nuclear membrane has also been proposed.\textsuperscript{102} For FGF-R1 it was shown that soluble cytoplasmic and nuclear forms and, on the other hand, plasma membrane receptors represent separated pools of different origin and with distinct functions.\textsuperscript{103} It has been proposed that FGF-R1 is synthesized at ER-attached polyribosomes and either enters Golgi, becomes extensively glycosylated and reaches the plasma membrane or, in non-glycosylated form, exits pre-Golgi vesicles and translocates as soluble cytoplasmic form complexed with RSK1 into the nucleus via nuclear pores.\textsuperscript{103} The origin of the soluble form of nTRAIL-R2 as well as the mode of its nuclear translocation is currently completely unknown. The receptors may either originate from the plasma membrane or from the non-nuclear soluble cytoplasmic receptor pool. The latter pathway seems to be more likely, as neither inhibition of endogenous secreted or plasma membrane expressed TRAIL via neutralizing antibodies nor the treatment of cells with recombinant TRAIL influenced the nuclear levels of TRAIL-R2.\textsuperscript{16} Two nuclear localization sequences (NLS) have been identified in TRAIL-R2. It has been reported recently that mutation of these sequences or knockdown of importin-\( \beta \) resulted in a diminished nuclear presence of TRAIL-R2 and, in parallel, enhanced expression at the plasma membrane.\textsuperscript{69} In contrast to this study, experiments performed in our laboratory using the same NLS-mutated TRAIL-R2 form did not reveal any impact of these NLS sequences on the nuclear import of the recombinant TRAIL-R2 in Panc1 and MDA-MB-231 cells (A. Trauzold, unpublished observations). However, we cannot rule out that the overexpressed NLS-mutated TRAIL-R2 interacts with endogenous TRAIL death receptors and utilize them as Trojan horses for nuclear import in these cells. Further studies are necessary to clarify the exact mechanisms of the translocation of TRAIL-R2 to the nucleus.

Another important question concerns the mechanism(s) by which nTRAIL-R2 inhibits the Drosha-mediated processing activity toward pri-let-7. Drosophila and DGR8 constitute the core of the Microprocessor complex that associates with multiple accessory proteins as hnRNPA1, p68, KSRP, NF45 and NF90. The core complex is capable of pri-miRNA processing in the absence of cofactors, whereas the associated factors in the larger complex may facilitate or alter the selectivity of nuclear miRNA processing.\textsuperscript{104} Accordingly, pri-let-7 is processed in a complex manner involving stimulatory factors (p68 and KSRP) as well as inhibitors (hnRNPA1, NF45 and NF90; Figure 3).\textsuperscript{105-109} It seems likely that nTRAIL-R2 modulates the pri-let-7 processing by interaction with NF45, hnRNPA1 and p68.\textsuperscript{16} This may be facilitated by either sequestration of activators or stabilization of an inhibitory complex.

It can be assumed that via its interaction with aforementioned proteins, nTRAIL-R2 might also influence the maturation of other miRNAs in addition to let-7. In this respect it is worth mentioning that p68 has been implicated in the recognition of a subset of pri-miRNAs targeting these for Drosha-mediated processing.\textsuperscript{110} Analysis of global changes of miRNA levels in cells with knockdown of TRAIL-R2 indicates the existence of further TRAIL-R2-regulated miRNA, besides the members of the let-7 family being most prominently represented.\textsuperscript{16} However, the array results have to be independently verified and, in addition, the question of whether these miRNAs are regulated by nTRAIL-R2 or by plasma membrane-expressed TRAIL-R2 remains to be answered.

Further investigations should also tackle the structural basis for the interactions of nTRAIL-R2 with proteins of the Microprocessor complex. As the core components Drosha and DGR8 were found to interact with TRAIL-R2 in an indirect manner, attempts should be made to delineate the physical contact sites between TRAIL-R2 and the accessory proteins, that is, hnRNPA1, p68, NF45 and NF90. Insights into the structural constraints of the interaction sites might allow the design of pharmacological inhibitors of these interactions, opening opportunities for targeted therapeutic interventions in the future.

Conclusions and Future Prospects

In spite of more than a decade of research on TRAIL death receptors, until very recently only their canonical signaling functions at the plasma membrane or within the endosomal/lysosomal compartment have been investigated. However, a number of reports also pointed to the intracellular presence of TRAIL-R1 and TRAIL-R2. In intracellular compartments, TRAIL death receptors are likely to neither contribute to canonical apoptosis signaling nor to non-apoptotic signal transduction, regardless of whether they are soluble within cytosol, trapped within the trans-Golgi network, in autophagosomes or are present in the nucleus. The elevated intracellular expression of TRAIL death receptors in cancer and the emerging evidence for their compartmentalization-dependent functions make clear that it is not sufficient to determine the general receptor expression in cells or tissues in a given experimental context. Instead, it is important to perform differentiated analyses of the subcellular distribution of receptors for the understanding of both the molecular biology and the disease-related relevance of TRAIL death receptors, especially when conclusions on the impact of these receptors for disease prognosis are drawn.

Now, a first study has demonstrated a functional impact of the nuclear localization of TRAIL death receptors in cancer cells. TRAIL-R2 was found to associate with components of the large Microprocessor complex inhibiting the processing of pri-let-7 miRNA. This strongly augments the malignant potential of these tumor cells. Such an effect of nTRAIL-R2 on miRNA processing is clearly distinct from the known nuclear functions of other cell surface receptors as EGFR family members, other RTKs or cytokine receptors that can modulate DNA-associated processes like replication, transcription or DNA damage repair and RNA splicing.

Thus, these novel findings will stimulate the search for unknown TRAIL-R2-specific nuclear functions, among them regulation of other miRNAs and possibly also RNA- and DNA-targeting mechanisms. This will further broaden the range of possibly affected nuclear regulatory processes of plasma membrane receptors that emerge as important regulators in the cell nucleus. The findings on a specific function of...
nTRAIL-R2 should also promote the search for possible unknown nuclear functions of other members of the death receptor family. In this respect, the capability of TRAIL-R1 and TRAIL-R4 to specifically interact with TRAIL-R2 in the nucleus also raises the question of the capacity of these receptors to modulate the nuclear functions of TRAIL-R2. Finally, these recent insights into TRAIL receptor biology might open new perspectives for anti-cancer therapies targeting processes regulated by nTRAIL-R2.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. Our research was supported by the Deutsche Forschungsgemeinschaft (PCC-Kiel/project TR 1063/2-1; SKELMET FOR 1586/project TR 1063/3-1). Investigation of clinical specimens was supported by the P2N Forschungsgemeinschaft (PCC-Kiel/project TR 1063/2-1; SKELMET FOR 1586). The authors declare no conflict of interest.

References

1. Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–113.
2. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386–5397.
3. Screaton GR, Mongkolpisay J, Xu XN, Cowper AE, McMichael AJ, Bell JL. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693–696.
4. Pan G, Ni J, Wei YF, Yu G, Gentz R, Distl VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.
5. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBoise RF et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170.
6. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820.
7. Schneider P, Thome M, Burns K, Bodmer J, Hofmann K, Kataoka T et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831–838.
8. Emery-JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–14367.
9. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
10. Walczak H, Miller RE, Arai K, Giliani B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
11. Dinberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32: 1341–1350.
12. Micheau O, Shirley S, Dutour F. Death receptors as targets in cancer. Br J Pharmacol 2013; 169: 1723–1744.
13. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16: 1701–1708.
14. Röder C, Trauzold A, Kalthoff H. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 2011; 90: 455–465.
15. Azijli K, Weyhenmeyer B, Peters GW, de Jong S, FAE Krust. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 2013; 20: 858–868.
16. Haselmann V, Kurz A, Bertsch U, Hübsner S, Olemposka-Müller M, Fritsch J et al. Nuclear death receptor TRAIL-R2 inhibits maturation of Let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014; 146: 278–290.
17. Gallmeier E, Bader DC, Kreig L, Bereczka S, Seeliger H, Goke B et al. Loss of TRAIL receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS One 2013; 8: e56760.
28. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of Li Y, Jin X, Li J, Jin X, Yu J, Sun X et al. J Cell Death and Disease 2013; 6: 253–264.

29. Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S et al. Mol Cancer Ther 2006; 5: 2229–2236.

30. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, et al. J Immunol 2013; 190: 371–379.

31. Niu Y, Li Y, Zang J, Huang H, Deng J, Cui Z et al. J Biol Chem 2012; 287: 2003–2014.

32. Kaebisch M, Gessner C, Berg D, Dimitrova DP, Feoktistova M, Siegmund M et al. Molecular Cancer 2012; 11: 229–241.

33. Wurnberg NB, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME. J Biol Chem 2012; 287: 1253–1264.

34. Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME et al. Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 2009; 136: 2365–2376.

35. Herlitz M, Uwegba U, de Vries EG, Timens W, Groen HJ, Boezen HM et al. Cell Death Differ 2012; 19: 2003–2014.

36. Voigt S, Philipp S, Davavina P, Winoto-Morbach S, Roder C, Arentz C et al. Cell Death Differ 2012; 19: 2003–2014.

37. Azijli K, Yuvare J, Peppelenbosch MP, Wurding T, Decker H, Jorje et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-RIP3-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci 2012; 125: 4651–4661.

38. Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of Earth M, Fischl H, Debatin KM et al. J Biol Chem 2012; 287: 2253–2264.

39. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, et al. Cell Death Differ 2013; 20: 652–653.

40. Oikonomou E, Kosmidou V, Katsel E, Kordiotis D, Moutouzkou D, Kontogeorgos G et al. TRAIL receptor upregulation and the implication of KRA/SBRAF mutations in human colon cancer tumours. Int J Cancer 2009; 125: 2127–2135.

41. Zhuang ZD, Franco AV, Nguyen T, Gray CP, Hersey P. Different localization and differential expression of TRAIL death receptors in human melanoma. Oncology 2003; 65: 1172–1184.
68. Leithner K, Stacher E, Wurm R, Ploner F, Quehenberger F, Wichtlhofer C et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 2009; 65: 98–104.

69. Kojima Y, Nakayama M, Nishina T, Nakao H, Koyanagi Y, Nakeda K et al. Importin beta protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF) induced apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. J Biol Chem 2011; 286: 43383–43393.

70. Petemel S, Prip-Cassar M, Manestar-Blazic T, Brijac I, Kestelan M. Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis. Arch Dermatol Res 2011; 303: 389–395.

71. Lee YS, Dutt A. A tumor suppressor microRNA let-7 represses the HMGAA2 oncogene. Genes Dev 2007; 21: 1025–1030.

72. Park SM, Shiel S, Radjabi AR, Schickel R, Feig C, Boyerinas B et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGAA2. Cell Cycle 2007; 6: 2585–2590.

73. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R et al. Nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol 2011; 31: 4323–4332.

74. Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana E. Nuclear epidermal growth factor receptor nuclear import is linked to activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 1015–1026.

75. Wang YN, Hung MC. Nuclear functions and subcellular trafficking mechanisms of the tumor suppressor microRNA let-7. Mol Cancer 2010; 9: 245–258.

76. Hu Y, Fang X, Dunham SM, Prada C, Stachowiak EK, Stachowiak MK. 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling. J Biol Chem 2004; 279: 29235–29243.

77. Weng, FC, Gu, H, Zhang X, Zhou, Y, Han, Y, et al. Nuclear targeting of type I transforming growth factor-β receptor and increased nuclear accumulation after growth arrest. Exp Cell Res 2000; 258: 121–134.

78. Chang, B, Wang, L, Xu, Y, et al. Nuclear translocation of type I transforming growth factor β receptor confers a novel function in rRNA processing. Mol Cell 2012; 32: 2183–2195.

79. Zhou, H, Pham, L, Tamayo, A, Lin-Lee, YC, Fu, L, Yoshimura, LC et al. Nuclear CD40 interacts with c-rel and enhances proliferation in aggressive B-cell lymphoma. Blood 2007; 110: 2121–2127.

80. Fu, LC, Lin-Lee, YC, Pham, LV, Tamayo, AT, Yoshimura, LC, Ford, RJ. BAFF-R promotes cell proliferation and survival through interaction with IKK beta and NF-kappa B-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009; 113: 4627–4636.

81. Liao HJ, Carpenter G. Role of the S6d1 translocin in EGF receptor trafficking to the nucleus and gene expression. Mol Cell Biol 2007; 18: 1064–1072.

82. Gir, D, Ali-Sayed M, Li, LY, Lee, DF, Ling, P, Sarthotheses G et al. Endosomal transport of eIF-2B is required for nuclear entry of the cell surface receptor. Mol Biol Cell 2006; 17: 11005–11018.

83. Wang YN, Yamaguchi H, Liu D, Yu L, et al. The translocin S6d1beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem 2010; 285: 38720–38729.

84. Duham-ems SM, Pudavar HE, Myers JM, Maher PA, Frasad PN, Stachowiak MK. Factors controlling fibroblast growth factor receptor-1’s cytoplasmic trafficking and its regulation as revealed by FRAP analysis. Mol Cell Biol 2006; 17: 2223–2235.

85. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Drorostaj B, Coon N et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235–240.

86. Salzman DW, Shubert-Coleman J, Funeaux H. P68 RNA helicase unwinds the human let-7 microRNA precursor duplex and is required for let-7-directed silencing of gene expression. J Biol Chem 2007; 282: 32773–32777.

87. Suzuki H, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460: 529–533.

88. Brubach B, Brisa T, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 2009; 469: 1013–1014.

89. Michlewski G, Caceres JF. Antagonistic role of hnrNPA1 and KSRP in the regulation of let-7a biogenesis. Nat Struct Mol Biol 2010; 17: 1011–1018.

90. Sakamoto S, Aoki K, Higuchi T, Todaka H, Morisawa K, Takami N et al. The NF90/NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol 2009; 29: 3754–3769.

91. Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshiba I, Yoshimura K et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 2007; 9: 604–611.